GC Biopharma Corp. (KRX:006280)
South Korea
· Delayed Price · Currency is KRW 127,500
+300 (0.24%)
At close: Jun 2, 2025, 3:30 PM KST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
| Manufacturing and Sales of Pharmaceuticals, Etc. | 1,440.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Manufacturing and Sales of Pharmaceuticals, Etc. Growth | -2.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnosis and Analysis of Samples, Etc. | 213.76B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnosis and Analysis of Samples, Etc. Growth | -18.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation | -46.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation Growth | -19.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 18.50B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -16.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Corporation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Corporation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Medical Science Corporation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Medical Science Corporation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross WellBeing Corporation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross WellBeing Corporation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Lab Cell Corporation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Lab Cell Corporation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Invanfarm Corporation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Invanfarm Corporation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Genome Corporation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Genome Corporation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Medis Corp. | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Green Cross Medis Corp. Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| GCC Corporation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| GC DO Brasil Participacoes LTDA | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation | -46.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation Growth | -19.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
| Consolidation | -46.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation Growth | -19.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea | 1,400.27B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea Growth | -4.23% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas | 272.87B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas Growth | -11.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation | -46.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation Growth | -19.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|